DLL3 and small cell lung carcinoma: Recently, Tarlatamab, a bispecific T-cell engager targeting both delta-like ligand 3 (DLL3) of cancer cells and CD3 on T-cells, was approved by FDA for ES-SCLC with disease progression on or after platinum-based chemotherapy [47,48].